RCS - Oxford Biomedica PLC - John Dawson awarded CBE in New Year Honours List

Oxford BioMedicaAnnouncement

04/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220104:nRSD2523Xa&default-theme=true

RNS Number : 2523X  Oxford Biomedica PLC  04 January 2022

 

 

John Dawson awarded CBE in the Queen's New Year Honours List

Oxford, UK - 4 January 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group"), a leading gene and cell therapy group, is pleased
to announce that the Group's Chief Executive Officer John Dawson has been
awarded a CBE (Commander of the Order of the British Empire) for services to
UK Life Science as part of the Queen's New Year Honours List.

Dr. Roch Doliveux, Chair of Oxford Biomedica, said: "I warmly congratulate
John for receiving this thoroughly deserved recognition. Thanks to his
foresight, Oxford Biomedica has grown to become a world leader in cell and
gene therapy, helping society during the COVID-19 pandemic and beyond. I and
the entire Board are extremely grateful to John for his warm and resilient
leadership and having built Oxford Biomedica as a world leader in viral
vectors for cell and gene therapy, enabling so many lives to be saved."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications: T: +44 (0)20 3709 5700

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim and Arcellx,
through which it has long-term economic interests in other potential gene and
cell therapy products. Additionally, the Group has signed a 3-year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222.
Oxford Biomedica is based across several locations in Oxfordshire, UK and
employs more than 740 people. Further information is available at www.oxb.com
(http://www.oxb.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUUCGUPPPGW